Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
/in Dendritic Cells, Endometrial Cancer, International Publications, Ovarian Cancer /von 2002-01-07 / Br. J. Cancer 2002 Jan;86(1):151-7Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2002-01-01 / Med. Oncol. 2002;19(4):213-8The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2002-01-01 / Int J Gastrointest Cancer 2002;32(1):1-6Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression
/in Dendritic Cells, International Publications, Soft Tissue Sarcoma /von 2001-12-01 / Cancer Res. 2001 Dec;61(23):8513-9Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2001-10-01 / J. Clin. Endocrinol. Metab. 2001 Oct;86(10):4965-9Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells
/in Dendritic Cells, Glioblastoma, International Publications /von 2001-09-01 / Cancer Immunol. Immunother. 2001 Sep;50(7):337-44Immunotherapy of multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2001-07-01 / Semin. Hematol. 2001 Jul;38(3):260-7Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2001-06-26 / Proc. Natl. Acad. Sci. U.S.A. 2001 Jul;98(15):8809-14The use of dendritic cells in cancer therapy
/in Dendritic Cells, International Publications /von 2001-06-01 / Lancet Oncol. 2001 Jun;2(6):343-53IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de